Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cipaglucosidase alfa/miglustat in pediatric infantile-onset Pompe disease
2022-501095-25-01Phase 3Authorised
- Sponsor
- Amicus Therapeutics
- Start
- Oct 2023
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, open-label trial of cipaglucosidase alfa in Pompe disease (2 cohorts), sponsored by Amicus Therapeutics. Planned start Oct 2023; status: authorised.
02
Drugs
cipaglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on 2022-501095-25-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501095-25-01.